About TumourTrace
TumourTrace is a company based in Nottingham (United Kingdom) founded in 2014. It operates as a B2B. TumourTrace operates in a competitive market with competitors including Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
- Headquarter Nottingham, United Kingdom
- SectorsHealthcare
- Website tumourtrace.com
- Social X
- Latest Funding Round$55.82K (USD), Grant
Aug 2016
- InvestorsEuropean Union
& 1 more
Funding Insights of TumourTrace
- Total Rounds 3
- Last Round Grant — $55,822
- Investors Count 2
All 3 funding rounds of TumourTrace with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2016 | $55,822 | Grant | – | – | |
| Mar 2016 | $54,360 | Grant | – | – | |
| Jan 2016 | – | Grant | – | – | – |
2 investors in total: 2 institutional.
Investors in TumourTrace
TumourTrace has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for TumourTrace
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TumourTrace
3 dated milestones of TumourTrace across 2 years, from founding to its latest funding, stage changes and deals.
- Founded TumourTrace is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $56K.
Competitors of TumourTrace
TumourTrace operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. |
Detailed competitors of TumourTrace
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tumourtrace
Complete news archive for TumourTrace
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to TumourTrace
10 companies that operate in the same segment as TumourTrace (Imaging Diagnostics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 190 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.17 M | – | 242 | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M | – | – | |
Planar X-ray radiology products for diagnostic imaging are supplied. | 2000 | Oxford, Oxfordshire, United Kingdom | USD 43.43 M | USD 1.04 M | 50 | |
Digital X-ray sources are developed by Nanox for cloud-based diagnostics. | 2004 | Jerusalem, Jerusalem District, Israel | USD 110.72 M | USD 13.02 M | 165 | |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | 2007 | Los Angeles, California, United States | USD 59.64 M | – | – | |
Portable wireless ultrasound systems are developed for medical imaging. | 2014 | Burnaby, British Columbia, Canada | USD 21.87 M | – | – | |
Portable MRI systems are manufactured for medical professionals. | 2014 | New York, New York, United States | – | USD 13.56 M | 111 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TumourTrace
TumourTrace was founded in 2014 and raised its 1st funding round 2 years after it was founded.
TumourTrace is headquartered in Nottingham, United Kingdom.
TumourTrace, founded in 2014 in Nottingham, United Kingdom, focuses on providing healthcare solutions, medical diagnostics, cancer detection, and early diagnostics. Offers early diagnostic tools for detecting solid tumors. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
TumourTrace's top competitors include Guardant Health, Strand Life Sciences and Juno Therapeutics.
TumourTrace has 2 investors. Key investors include European Union, and EIC Fund.